The FDA on April 5, 2022, granted accelerated approval to VIJOICE® for adult and pediatric patients two years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy. VIJOICE® is a product of Novartis Pharmaceuticals Corporation.
Other Pages – Bottom Ad
Advertisement
Subscribe
